Emergent Releases Inaugural ESG Report

November 18, 2021

GAITHERSBURG, M.D. – Emergent BioSolutions (NYSE: EBS) today released the inaugural edition of its environmental, social and governance (ESG) report. The report documents Emergent’s approach to ESG, as well as key areas of focus.

“Emergent has always prioritized being a good and responsible corporate citizen, both in how we run our business and how we engage with our employees and communities,” said Emergent CEO Robert G. Kramer. “Corporate responsibility is a journey, not a destination, and I am proud of what we have been able to accomplish and confident in our strategy for continuous improvement.”

The COVID-19 pandemic defined 2020, and as the report details, Emergent employees stepped up to play their part by taking on unprecedented tasks while learning to work in a new environment. Their efforts resulted in production of bulk drug substance to support hundreds of millions vaccine doses helping patients all around the world. Additionally, the team remained focused on the opioid overdose epidemic and increased education and accessibility of NARCAN® Nasal Spray to aid in the reversal of suspected opioid overdoses.

This inaugural report also details:

· Emergent’s commitment to employees and a culture that values diversity, emphasizes equity and practices inclusion.

· Emergent’s approach to environmental sustainability.

· Emergent’s focus on governance, compliance and quality.

· Emergent employees’ dedication to their communities.

The ESG report is based on Emergent’s assessment of key sustainability frameworks, primarily, the Sustainability Accounting Standards Board (SASB) standards focused on the Healthcare – Biotechnology and Pharmaceuticals industries, the Taskforce on Climate-related Financial Disclosure (TCFD), and the United Nation’s Sustainable Development Goals.

The entire report can be found here.